Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced today (October 23, 2025) that its lead candidate, Telomir‑1, has produced new preclinical data in an in‑vivo study of mice bearing human aggressive prostate cancer tumors. The study evaluated DNA‑methylation changes in two critical defense genes—CASP8 and GSTP1—after treatment with oral Telomir‑1, Rapamycin, chemotherapy, and combination regimens.
The data reveal that Telomir‑1 restores epigenetic regulation of CASP8 and GSTP1 more effectively than Rapamycin and standard chemotherapy, indicating a superior ability to reactivate cell‑death pathways and glutathione‑based detoxification mechanisms that are often disrupted in cancer.
These findings provide the first in‑vivo evidence of Telomir‑1’s mechanism of action in a clinically relevant cancer model, strengthening the company’s case for advancing the drug toward IND filing and human trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.